In 2016, immunotherapy marked a significant advancement in MCC treatment with the introduction of PD1/PDL1 immune-checkpoint inhibitors (ICI), showing efficacy in some patients with MCC. This evidence concerns the gene CD274 and Merkel cell skin cancer.